Twitter Thread by JST Investments



JST Investments
@JstInvestments

Key insights from Hikal

■ Lowered interest rates
■ Pharma: Growth in generics as well as CDMO
■ Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
■ Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa

> Hikal: Strong
>
> \U0001f9ea Rev up 27% YoY
> \U0001f9ea 22% EBITDA margin
> \U0001f9ea Pat of 50crs
> \U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe
>
> — JST Investments (@JstInvestments) August 5, 2021